Do you want to read an article? Please log in or register.
Characteristics of pulmonary complications in non-Hodgkin's lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
Further Publications
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM
doi: 10.1016/j.cllc.2020.07.016.
Pulmonary Hypertension
The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension
Eur Respir J.
Quadery SR, Swift AJ, Billings C, Thompson A, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong I, Hamilton N, Sephton P, Garrod S, Pepke-Zaba J, Jenkins DP, Screaton N, Rothman AM, Lawrie A, Cleveland T, Thomas S, Rajaram S, Hill C, Davies C, Johns CS, Wild JM, Condliffe R, Kiely DG
doi: 10.1183/13993003.
RECOMMENDED
Pulmonary Fibrosis
Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, Sarma N, Ma SF, Haczku A, Sperling A, Strek ME, Noth I, Oldham JM
doi: 10.1016/j.chest.2020.04.066.
RECOMMENDED
Further Publications
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, CameL Study Group.
doi: 10.1016/S2213-2600(20)30365-9
RECOMMENDED
Pulmonary Hypertension
Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
Eur Respir J.
Delcroix M, Staehler G, Gall , Grünig E, Held M, Halank M, Klose H, Vonk-Noordegraaf A, Rosenkranz S, Pepke-Zaba J, Opitz CF, Gibbs JSR, Lange TJ, Tsangaris I, Huscher D, Pittrow D, Olsson KM, Hoeper MM
doi: 10.1183/13993003.
Lung Cancer
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Lancet Oncol.
Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN
doi: 10.1016/
RECOMMENDED
Lung Cancer
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M
doi: 10.1016/j.lungcan.2021.04.022
RECOMMENDED
Lung Cancer
Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T
doi: 10.1016/j.cllc.2020.05.024.
RECOMMENDED
Lung Cancer
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Goulart BHL, Chennupati S, Fedorenko CR, Ramsey SD
doi: 10.1016/j.cllc.2021.01.019